Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
10
×
Tags
drugs
10
×
life sciences
10
×
national blog main
clinical trials
boston blog main
boston top stories
biotech
fda
national top stories
new york blog main
new york top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
amgen
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
national
san francisco top stories
seattle blog main
seattle top stories
svb leerink
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
calcitonin gene-related peptide
cancer
marc goodman
medicxi
migraine
What
new
10
×
drug
fda
medicine
approved
data
alnylam
approval
class
drugs
far
medicines
migraine
oks
pharmaceuticals
rna
second
won
advance
aldeyra
announced
arguments
based
big
bio
biologic
biology
biopharma
brexanolone
cancer
cash
cholesterol
cleared
closer
commercialized
committed
companies
competitors
congress
congressional
Language
Current search:
new
×
photo
×
" life sciences "
×
drugs
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Hatteras Launches New Fund With $94M for Life Science Investments
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs